Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Research Frontiers Inc. announced its first-quarter 2026 financial results, noting revenue was impacted by the timing of license agreement recognition and absence of prior year upfront revenue. The company advanced multiple strategic initiatives across automotive, aircraft, and architectural sectors using its SPD-Smart light-control technology. Whi…
Corvus Pharmaceuticals reported positive Phase 1 clinical data for its lead drug candidate, soquelitinib, in atopic dermatitis and initiated Phase 2 trials including additional indications like hidradenitis suppurativa and asthma. The company also continues enrolling in a Phase 3 trial for T cell lymphoma and collaborates with NIAID on a rare disea…
Gevo, Inc. announced solid financial and operational results for Q1 2026, exceeding expectations despite seasonality in ethanol margins. The company progressed on its debottlenecking and expansion projects at its North Dakota facility to increase low-carbon ethanol output by over 10% next year and aims to double capacity by 2028. Gevo also launched…
Denali Therapeutics announced FDA accelerated approval and U.S. commercial launch of AVLAYAH for Hunter syndrome, the first medicine leveraging the transferrin receptor to cross the blood-brain barrier. The company reported progress across its pipeline targeting Alzheimer's, frontotemporal dementia, Sanfilippo syndrome, Pompe disease, and Parkinson…
Annexon, Inc. reported its first quarter 2026 financial results and detailed significant progress and upcoming milestones across its neuroinflammatory disease therapy portfolio. Key upcoming catalysts include topline Phase 3 data for vonaprument targeting Geographic Atrophy (GA) expected in Q4 2026, regulatory review of tanruprubart for Guillain-Ba…
SIGA Technologies announced its financial results for Q1 2026, reporting net losses but highlighted planned deliveries of $13 million oral TPOXX to an international customer and $26 million IV TPOXX to the U.S. Government Strategic National Stockpile by Q3 2026. The company also secured an exclusive license agreement for oral TPOXX commercializatio…
Akamai Technologies reported first quarter 2026 revenue of $1.074 billion, a 6% increase year-over-year driven primarily by 40% growth in Cloud Infrastructure Services and 11% growth in security revenue. The company announced a $1.8 billion seven-year commitment from a leading U.S.-based frontier model provider in AI, validating Akamai's position i…
Senseonics Holdings, Inc. reported robust first quarter 2026 financial results with revenue growing 87% year-over-year to $11.7 million. The company highlighted significant commercial progress, including the US launch of Eversense 365 and expansion into Europe. They raised over $100 million in equity and debt financing to support ongoing product co…
Voyager Therapeutics announced its first quarter 2026 financial results and operational progress, highlighting completion of IND-enabling toxicology studies for its tau silencing gene therapy VY1706, with first-in-human dosing expected in the second half of 2026 for Alzheimer's disease. The company maintains a strong cash position of $172 million, …
BridgeBio Pharma reported first quarter 2026 financial results highlighting $194.5 million in total revenues, primarily driven by $180.6 million from U.S. sales of its ATTR-CM drug Attruby. The company continues to see strong commercial traction for Attruby, including new approval in Brazil. It has submitted its first NDA for BBP-418 (LGMD2I/R9) an…
Xenon Pharmaceuticals announced positive topline Phase 3 data from the X-TOLE2 study for azetukalner in focal onset seizures, leading to an anticipated New Drug Application submission to the FDA in Q3 2026. The company continues enrollment in additional Phase 3 trials for epilepsy and neuropsychiatric indications and advances early-stage pain candi…
Clearway Energy, Inc. reported Q1 2026 results with a net loss of $68 million, Adjusted EBITDA of $257 million, and reassured full-year 2026 CAFD guidance of $470 to $510 million. The company progressed significant growth initiatives, including completion of the Honeycomb Phase 1 battery storage facilities, acquisition of the Cardinal solar portfol…
Prairie Operating Co., an independent energy company focused on oil and natural gas development in the Denver-Julesburg Basin, will release its first quarter 2026 financial and operating results on May 14, 2026, followed by a conference call on May 15. The company invites analysts and investors to participate as it provides updates on recent develo…
Tectonic Therapeutic announced its Q1 2026 financial results highlighting significant clinical progress with TX45 and TX2100 drug candidates targeting pulmonary hypertension and hereditary hemorrhagic telangiectasia (HHT). Key milestones include near completion of patient enrollment in TX45 APEX Phase 2 trial, initiation of TX45 ALPINE Phase 2 tria…
Celldex has successfully completed enrollment for its Phase 3 studies in chronic spontaneous urticaria (CSU) six months ahead of schedule, with topline data expected in Q4 2026 and a planned BLA submission in 2027. Ongoing studies include Phase 3 trials for cold urticaria and symptomatic dermographism, and a Phase 1 study of CDX-622 in asthma. The …
Bluejay Diagnostics provided a Q1 2026 update highlighting progress in clinical enrollment, manufacturing readiness, and regulatory strategy for its Symphony IL-6 test aimed at rapid sepsis patient monitoring. The company enrolled approximately 680 patients in its pivotal SYMON-II study, advanced manufacturing with contract manufacturer Sanyoseiko,…
Quest Resource Holding Corporation announced its Q1 2026 financial results showing a 4.8% sequential revenue increase and 6.1% rise in gross profit from Q4 2025, despite year-over-year declines. The company onboarded new customers, including a large quick-service restaurant franchisee, and refinanced debt to reduce interest expenses. Quest focused …
Serve Robotics announced robust first quarter 2026 results with revenue of $3.0 million, up 238% sequentially and 578% year-over-year, reflecting expansion across delivery and healthcare robotics following the acquisition of Diligent Robotics. The company expanded operations to 44 cities in 14 states, grew its robot fleet to approximately 2,000 uni…
Amneal Pharmaceuticals reported a solid start to 2026 with a 4% increase in Q1 net revenue to $723 million and a 411% jump in net income to $62 million compared to Q1 2025. Adjusted EBITDA rose 19% to $202 million, driven by strong performance across its Specialty and Affordable Medicines segments. The company also reaffirmed its previously raised …
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company focused on Alzheimer’s disease therapeutics, announced management's participation in a fireside chat at the Bank of America Securities 2026 Health Care Conference. The company is advancing its lead drug candidate, sabirnetug (ACU193), targeting toxic amyloid beta oligomers, currentl…
INmune Bio Inc., a NASDAQ-listed clinical-stage immunology company, announced a reduced net loss of $5.4 million for Q1 2026 versus $9.7 million in Q1 2025, reflecting lower R&D expenses. Key milestones include UK MHRA pre-submission for CORDStrom™, anticipated regulatory filings in the UK, EU, and US later this year, new Phase 2 imaging data for X…
Assembly Biosciences announced steady progress in Q1 2026, completing Phase 1b studies for two herpesvirus drug candidates, completing toxicology studies for a hepatitis delta virus candidate, and preparing for a Phase 2 initiation later in 2026. The company also reported a strong cash position projected to fund operations into 2028, despite a net …
UroGen is shifting from development to commercialization as ZUSDURI rollout accelerates. With market cap near $1.3B, negative EPS but improving commercial signals and elevated short interest, this is a directional long for investors who want exposure to a commercial-stage bladder cancer franchise heading toward profitability by 2027.
A director at Bank of the James Financial Group Inc. has increased his position in the firm through a recent open-market purchase. This transaction follows a period of notable financial expansion for the company, which reported a substantial surge in first-quarter net income and earnings per share compared to the prior year.
Options pricing suggests Nano Nuclear Energy Inc. (NYSE:NNE) could see its share price move about 4% when it reports earnings on May 14 after markets close. Historical reactions to prior earnings have varied, with three of the past six announcements producing share swings larger than options-implied expectations and three producing smaller moves.
